Journal article : Review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Abstract:: Background
Regularly transfused people with sickle cell disease (SCD) and people with thalassaemia are at risk of iron overload. Iron overload can lead to iron toxicity in vulnerable organs such as the heart, liver and endocrine glands, which can be prevented and treated with iron‐chelating agents. The intensive demands and uncomfortable side effects of therapy can have a negative impact on daily activities and wellbeing, which may affect adherence.
Objective... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Geneen, L. J., Dorée, C., & Estcourt, L. J. (2023). Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database of Systematic Reviews, 2023(3).

MLA Style

Geneen, L. J., et al. “Interventions for Improving Adherence to Iron Chelation Therapy in People with Sickle Cell Disease or Thalassaemia.” Cochrane Database of Systematic Reviews, vol. 2023, no. 3, Wiley, 2023.

Chicago Style

Geneen, LJ, C Dorée, and LJ Estcourt. 2023. “Interventions for Improving Adherence to Iron Chelation Therapy in People with Sickle Cell Disease or Thalassaemia.” Cochrane Database of Systematic Reviews 2023 (3).
Share
Print

Access Document

Files:: Geneen_et_al_2023_Interventions_for_improving.pdf

(Preview, Version of record, pdf, 1.7MB, Terms of use)

Publisher copy:: 10.1002/14651858.cd012349.pub3

Authors

+ Geneen, LJ More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Role:: Author

+ Dorée, C More by this author

Role:: Author

+ Estcourt, LJ More by this author

Role:: Author

+ Department of Health and Social Care More from this funder

Publisher:: Wiley
Journal:: Cochrane Database of Systematic Reviews More from this journal
Volume:: 2023
Issue:: 3
Article number:: CD012349
Place of publication:: England
Publication date:: 2023-03-06
Acceptance date:: 2022-12-22
DOI:: 10.1002/14651858.cd012349.pub3
EISSN:: 1469-493X
Pmid:: 36877640

Language:: English
Keywords:: drug-related side effects and adverse reactions

FFR

drug therapy]

deferoxamine [adverse effects]

humans

child

chelation therapy

thalassemia

sickle cell [complications

chelating agents

anemia

iron
Subtype:: Review
Pubs id:: 1333477
Local pid:: pubs:1333477
Deposit date:: 2023-08-08

Terms of use

Copyright holder:: Cochrane Collaboration
Copyright date:: 2023
Rights statement:: © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP